Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis.
Barie
Philip S
PS
Division of Critical Care and Trauma, Weill Medical College of Cornell University, Payson 713A, 525 E. 68th St., New York, NY 10021, USA. pbarie@med.cornell.edu
Williams
Mark D
MD
McCollam
Jill Shwed
JS
Bates
Becky M
BM
Qualy
Rebecca L
RL
Lowry
Stephen F
SF
Fry
Donald E
DE
D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D011486:Protein C / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D018570:Risk Assessment; D013514:Surgical Procedures, Operative / Q000379:methods; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy* / Q000601:surgery; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated